Second-line erlotinib for non-small-cell lung cancer

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages

  Lorusso, Vito ^a   Cinieri, Saverio ^b  

^a VITO FAZZI HOSPITAL   (Italy)

^b Medical Oncology and Breast Unit Ospedale Perrino   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; GEFITINIB; IFOSFAMIDE; NAVELBINE; PEMETREXED; PLACEBO; VASCULOTROPIN;

ADVANCED CANCER; CANCER GROWTH; CANCER SURVIVAL; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84859134673     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70113-4     Document Type: Letter

References (9)

1. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012, 13:300-308.
2. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
3. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
4. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000, 18:2354-2362. and the TAX 320 Non-Small-Cell Lung Cancer Study Group.
5. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
6. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
7. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
8. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
9. Wu JY, Wu SG, Yang CH, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutation. Lung Cancer 2011, 72:205-212.